Sodium Chloride and Dextrose Injection (1:4)

Adult administration

Typically, an adult receives a single intravenous infusion of 500 to 1,000 mL. The infusion rate is 300 to 500 mL per hour (75 to 120 drops per minute).

Child administration

For pediatric patients, the infusion rate should be 50 to 100 mL per hour. In particular, do not perform rapid infusions (over 100 mL per hour) in newborns and premature infants.

This medication contains dextrose, which can increase the consumption of vitamin B1 in the body during intravenous administration. Therefore, there is a risk that a deficiency of vitamin B1 could suddenly become severe, requiring caution. It should not be used in conditions with excessive fluid overload, hypertonic dehydration, or in patients with low potassium levels in the blood. Use with caution in patients with impaired kidney function, heart failure, hypertonic dehydration, patients with reduced urine output due to urinary obstruction, diabetics, and patients with high blood chloride levels. Rapid or excessive administration of this medication may result in serious side effects such as cerebral edema, pulmonary edema, peripheral edema, acidosis, and water intoxication. Particularly in neonates or premature infants, rapid administration carries a high risk of water intoxication. Thrombosis may occur at the injection site, requiring observation. Regular monitoring of blood glucose, serum electrolytes, and fluid balance during administration is necessary to manage the condition effectively. The container of this medication may contain PVC material with DEHP as a plasticizer; however, the associated risks are very low, so there is no need to avoid use. During pregnancy, it should only be used when the therapeutic benefits outweigh the potential risks to the fetus. Administration during labor may cause abnormalities in blood glucose levels for both mother and newborn, so the benefits and risks should be carefully considered prior to administration. Close observation is necessary for neonates as they may experience severe complications due to the difficulty in blood glucose regulation, which can lead to hypoglycemia or hyperglycemia. Care should be taken not to administer rapidly or for prolonged periods in infants and the elderly. In elderly patients with heart failure or kidney failure, administration should be performed with extra caution to avoid circulatory overload. In cases of overdose, treatment may be required to control body fluids using diuretics. Before administration, the patient's skin and injection apparatus should be thoroughly disinfected, and the medication should be warmed to body temperature. Any remaining medication after opening should be discarded immediately. The injection should be administered slowly intravenously, and care should be taken to avoid air from being injected into the container to reduce the risk of air embolism. This medication should be stored at room temperature and can be safely used with proper handling and storage.

Serious side effects

Severe edema (cerebral edema, pulmonary edema, peripheral edema), urinary abnormalities (decreased urinary output), seizures (due to hypoglycemia), coma (due to hypoglycemia)

Mild side effects

• Cerebral edema
• pulmonary edema
• peripheral edema
• acidosis
• water intoxication
• hyperglycemia
• hypoglycemia
• thrombosis
• blood glucose abnormalities
• fluid imbalances

This medication should be stored in a sealed container at room temperature, between 1 to 30 degrees Celsius. Storing it this way will help maintain the medication's effectiveness.

Appearance

This medication is filled in a container made of colorless transparent glass or multilayer film made of polypropylene and polyvinyl chloride, containing a colorless and transparent liquid with a slight salty and sweet taste.

Package unit

500, 1000 milliliters